Data de publicação: 30/06/2020 - 17:59
The Oswaldo Cruz Foundation (Fiocruz) will sign an agreement with pharmaceutical company AstraZeneca for the acquisition of batches and transference of technology regarding the Covid-19 vaccine developed by the University of Oxford. The agreement will be the result of the cooperation between the Brazilian government and the pharmaceutic company, announced last Saturday, June 27, by the Ministry of Health.
This is a Advance Purchase Agreement...
Notícias
Data de publicação: 29/06/2020 - 15:14
Although respiratory symptoms are the best-known face of Covid-19, post-traumatic stress (PTSD), depression, and anxiety have also been described in patients with the disease. In an article published in Frontiers in Immunology, researchers of the Oswaldo Cruz Institute (IOC/Fiocruz) and of Universidade Federal Fluminense (UFF), in the state of Rio de Janeiro, discuss how the new coronavirus can affect mental health, pointing to neural,...
Notícias
Data de publicação: 18/06/2020 - 15:52
Almost R$ 6 million (around US$1,2 million) in tests for Covid-19, personal protective equipment (PPE) and test devices will be donated to state of Amazonas to face the new coronavirus. The material will be transferred by the Oswaldo Cruz Foundation (Fiocruz) Program, United Against Covid-19.
The distribution of products will be monitored by Leônidas & Maria Deane Institute (ILMD / Fiocruz Amazônia), explains the researcher...
Notícias
Data de publicação: 12/06/2020 - 11:57
The Institute of Technology in Immunobiological Products (Bio-Manguinhos/Fiocruz) is running a Brazilian project to develop a synthetic vaccine against the novel coronavirus (SARS-CoV-2). The studies are now advancing to a pre-clinical phase, in which safety aspects will be assessed in animal models. The synthetic form of the vaccine was chosen for being quicker than traditional methodologies, for its lower production costs, the stability of the...
Notícias
Data de publicação: 09/06/2020 - 17:18
During the first weeks of social distancing due to the Covid-19 epidemic, a great part of the Brazilian population reported mood issues. Forty percent felt sad or depressed and 54% felt anxious or nervous frequently. The percentages were even higher among young adults (between 18 and 29 years old): 54 and 70%, respectively.
This is one of the many results identified in the first phase of ConVid - Behavior Research, which aimed to...
Notícias
Data de publicação: 01/06/2020 - 16:56
The Fiocruz against Covid-19 will benefit, all over the country, 145 projects that focus on vulnerable populations, such as quilombos (rural afro-brazilian settlements), indigenous peoples, riverside populations and favela dwellers. The initiative reaches more than 80 municipalities in all Brazilian states. The projects were selected through a Public Call for Support to Emergency Actions against Covid-19 in Vulnerable Populations...
Notícias
Data de publicação: 25/05/2020 - 18:37
More than 7.8 million Brazilians are at least four hours away from a town where high-complexity healthcare is available, such as an intensive care unit (ICU), suitable equipment and staff specialized in severe and acute respiratory diseases as the one caused by the Covid-19 epidemic. This is one of the main conclusions of the most recent analysis by the Institute of Scientific and Technological Communication and Information in Health (Icict), of...
Notícias
Data de publicação: 25/05/2020 - 15:41
In another step of its actions to combat the pandemic of the new coronavirus, the Oswaldo Cruz Foundation (Fiocruz) built in less than two months a hospital unit for severe patients infected by the disease. Located in Manguinhos, headquarters of the Foundation in Rio de Janeiro, the Hospital Center for Pandemic Covid-19 - National Institute of Infectious Diseases Evandro Chagas (INI / Fiocruz) started receiving, on May 19, the first patients....
Notícias
Data de publicação: 14/05/2020 - 14:19
A research led by the Oswaldo Cruz Institute (IOC/Fiocruz) points out that the circulation of the novel coronavirus (SARS-CoV-2) started up to four weeks before the first cases were registered in countries in Europe and the Americas. The study, which uses a statistical methodology of inference from death records, indicates that, while countries were monitoring travelers and confirming the first imported Covid-19 cases, community transmission of...
Notícias
Data de publicação: 29/04/2020 - 12:19
Published in the JAMA Network Open, the initial results of the CloroCovid-19 trial show that patients with severe Covid-19 should not take high doses of chloroquine. The trial, whose goal is to assess the efficacy of two different dosages of the drug and has analised 81 patients with SARS (severe acute respiratory syndrome), is being led by more than 70 researchers, post-graduation students, and collaborators from renowned scientific...
Notícias
Data de publicação: 28/04/2020 - 18:43
The number of deaths caused by Covid-19 has doubled every 5 days in Brazil, on average. In the United States and in Ecuador, countries with high dissemination rates, the interval necessary for this duplication is an average of 6 days. In Italy and in Spain, 8 days.
This is one of the figures released by the most recent technical paper of MonitoraCovid-19, a system that groups and provides data on the pandemic of the new coronavirus in...
Notícias
Data de publicação: 28/04/2020 - 17:59
A group of researchers of the Oswaldo Cruz Foundation (Fiocruz) and of the Getulio Vargas Foundation (FGV) has just released a report on the risk of Covid-19 dissemination among indigenous populations, due to the geographic and sociodemographic vulnerability of this segment of the Brazilian population. According to the study, the arrival of Covid-19 has imposed many challenges to indigenous communities, to health authorities and to society as a...
Notícias
Data de publicação: 17/04/2020 - 14:29
Enhancing the actions of the Oswaldo Cruz Foundation (Fiocruz) in the view of the new coronavirus pandemic (Sars-CoV-2) by joining the forces of the public and private sectors. This is the goal of the United against Covid-19 program launched by Fiocruz on April 2nd, opening a channel for companies, organizations and individuals interested in being a part of the network of supporters for the initiatives developed by the institution, all over...
Notícias
Data de publicação: 15/04/2020 - 11:18
With the aim of presenting innovative initiatives to respond to the pandemic, researchers from the Foundation participated, on March 31, in a virtual workshop with Portuguese-speaking countries, organized by the Research Capacity Network (REDe) and the sharing knowledge base incorporated into the online platform The Global Health Network, from the University of Oxford. The platform aims to provide research resources, courses and other tools...
Notícias
Data de publicação: 14/04/2020 - 09:51
The Laboratory for Respiratory Viruses and Measles of the Oswaldo Cruz Institute (IOC/Fiocruz) has been nominated Reference Laboratory of the World Health Organization (WHO) for Covid-19 in the Americas. After the formalization of the agreement between the WHO and Fiocruz, the unit will now begin making confirmatory tests for the disease in the region, and will also join the WHO network of laboratory specialists for Covid-19.
National...
Notícias
Data de publicação: 09/04/2020 - 16:00
A Fiocruz research has observed that the drug Atazanavir, used against HIV, was able to inhibit viral replication and to reduce the production of proteins that are related to the inflammatory process in the lungs, and therefore to the worsening of the clinical symptoms of the disease. Specialists have also looked into the combined use of atazanavir and ritonavir, another drug used to fight HIV.
The study was published this Monday (April 6) on...
Notícias
Data de publicação: 06/04/2020 - 12:19
Fiocruz is now part of a group of more than 70 scientists and institutions of more than 30 countries in an international coalition to face the Covid-19 epidemic in countries with medium and low income. Launched last Thursday (02/04), the initiative, called Covid-19 Clinical Resarch Coalition, aims to speed up research on the new coronavirus in the areas where the virus may cause serious problems in health systems that are already fragile,...
Notícias
Data de publicação: 31/03/2020 - 14:34
The Foundation started the construction, in Rio de Janeiro, of the Hospital Center for the Covid-19 Pandemic - National Institute of Infectious Diseases, which will assist the state and municipal governments in fighting the disease. The rapid assembly hospital unit will have 200 beds exclusive for intensive and semi-intensive treatment of critical patients infected with the novel coronavirus (Sars-CoV-2). Check out a 3D view here.
Built in...
Notícias
Data de publicação: 31/03/2020 - 13:18
On March 24, the Oswaldo Cruz Foundation launched an express approval process at the Brazilian Registry of Clinical Essays (ReBEC) for clinical research on the Covid-19. The so-called fast track may reduce the normal approval period, which normally takes up to a couple of weeks, to less than 48 hours. Scientists all over the world will be able to have quick access to the modeling of ongoing studies, thus avoiding re-working and...
Notícias
Data de publicação: 31/03/2020 - 12:52
In an interview to the Fiocruz News Agency (AFN), Nísia Trindade Lima comments on the context of the Covid-19 pandemics and the challenges of its arrival in Brazil. The Fiocruz president also lists some of the actions taken by the institution as a response to this public health crisis, from the production of tests to health care to those infected. All departments and units of the Foundation are mobilized to face the epidemics....
Notícias
Data de publicação: 30/03/2020 - 14:04
An unprecedented study, conducted by the research group on Health in the Prisions [Saúde nas Prisões] of the National School of Public Health (Ensp/Fiocruz), and coordinated by Alexandra Sánchez, through technical cooperation with the Public Prosecutor's Office/RJ, analyzed the causes of deaths in the Prison System of the State of Rio de Janeiro (2016-2017). The results indicate that infectious diseases were...
Notícias
Data de publicação: 30/03/2020 - 11:09
Articles on the new coronavirus (Sars-CoV-2) can be published in just 24 hours in the journal Memórias do Instituto Oswaldo Cruz, one of the oldest and most respected scientific journals in Latin America.
Considering the importance of rapid data sharing during the pandemic, the journal provided an express way for the dissemination of research. Already used for work on Zika, chikungunya, yellow fever and Ebola, the Fast Track system...
Notícias
Data de publicação: 20/03/2020 - 13:24
The emergence of SARS-Cov-2 virus in Wuhan, China, in December 2019 led to a local epidemic that rapidly spread to multiple countries in the world, placing remarkable challenges in surveillance and control. On March 16th, 2020, WHO declared1 that the infection associated with SARS-Cov-2, named COVID-19, had spread to more than 100 countries, with more than 160,000 confirmed cases and more than 6,000 deaths globally.
Great uncertainty...
Notícias
Data de publicação: 19/03/2020 - 14:18
The Oswaldo Cruz Foundation (Fiocruz) will be sending a team of professionals to Portuguese-speaking countries in Africa to help organise the response to the new coronavirus pandemic. This cooperation answers to a request by the regional office of the World Health Organization (WHO) in Africa, received by Fiocruz last Sunday (March 15).
According to Fiocruz director of the Fiocruz Global Health Center, Paulo Buss, Brazilian and Portuguese...
Notícias
Data de publicação: 03/03/2020 - 11:33
Given the emergence of agents with the capacity to cause diseases in humans, such as the new coronavirus, the Covid-19, scientists from all over the world have begun to work hard on the search for answers on the behavior of the pathogen. The process is similar to assembling a jigsaw puzzle: at every new research, an increasingly robust set of data takes form, contributing to clarify important characteristics that are crucial to create an...
Notícias
O conteúdo deste portal pode ser utilizado para todos os fins não comerciais, respeitados e reservados os direitos morais dos autores.
